Intercell Announces Q4 and Preliminary Full Year 2010 Financial Results - PR Newswire (press release) PDF Print
PR Newswire (press release)
The study, conducted by Intercell's collaborator, Merck & Co., Inc., was designed to evaluate the safety and immunogenicity of the vaccine in patients with end-stage renal disease (ESRD) undergoing hemodialysis treatment.

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.